Eight young men were recruited to a study designed to examine the effect of tyrosine (TYR) supplementation on the capacity to perform prolonged exercise in a warm environment. Subjects entered the laboratory in the morning and remained seated for 1 hr before cycling to exhaustion at 70% VO 2peak . Two 250-ml aliquots of a placebo (PLA ) or a TYR solution were ingested at 30-min intervals before exercise, with an additional 150 ml consumed every 15 min throughout exercise (total TYR dose: 150 mg/kg BM). Cognitive function was assessed before drink ingestion, at the end of the rest period, and at exhaustion. TYR ingestion had no effect on exercise capacity (PLA 61.4 ± 13.7 min, TYR 60.2 ± 15.4 min; p = .505). No differences in heart rate (p = .380), core temperature (p = .554), or weighted mean skin temperature (p = .167) were apparent between trials. Ingestion of TYR produced a marked increase in serum TYR concentrations (+236 ± 46 μmol/L; p < .001), with this difference maintained throughout exercise. No change was apparent during the PLA trial (p = .924). Exercise caused an increase in error rate during the complex component of the Stroop test (p = .034), but this response was not influenced by the drink ingested. No other component of cognitive function was altered by the protocol (all p > .05). Ingestion of a TYR solution did not influence time to exhaustion or several aspects of cognitive function when exercise was undertaken in a warm environment.
Several studies have demonstrated a progressive impairment of exercise performance with increasing ambient temperature (Galloway & Maughan, 1997; Parkin, Carey, Zhao, & Febbraio, 1999) and relative humidity (Maughan, Otani, & Watson, 2012) . While there is compelling evidence that this early onset of fatigue is mediated through mechanisms residing within the periphery, including increased cardiovascular strain (Cheuvront, Kenefick, Montain, & Sawka, 2010) , several lines of research point to significant contribution of the central nervous system (CNS) in the fatigue process. Hyperthermia results in a profound effect on several aspects of CNS function, including brain activity, voluntary muscle activation, and motivation to continue exercise (Nybo, 2010) . This central response may serve as a protective mechanism to limit further heat production from the exercising muscles before serious damage can occur to the body's tissues (Lagrange, 1889; Watson et al., 2005) .
The CNS response to exercise involves the complex interplay of several different neurotransmitter systems, but it has become increasingly apparent that the catecholamine neurotransmitters play a significant role in exercise performance (Gerald, 1978; Watson et al., 2005) . Dopamine (DA) and noradrenaline (NA) have been implicated in arousal; motivation, reinforcement, and reward; the control of motor behavior; and mechanisms of addiction. Classical studies highlighted the strong role of DA in motivated behaviors (Olds & Milner, 1954) , and intracranial stimulation of the ventral tegmental area, a region of the brain dominated by dopaminergic projections, has been shown to encourage rats to run without the need for aversive electric shocks (Burgess, Davis, Borg, & Buggy, 1991) . Elevations in extracellular DA and NA have been reported during exercise in several cerebral regions including the striatum (Meeusen, Smolders, et al., 1997) and hypothalamus . In addition, a marked fall in brain-tissue DA content has been observed at the point of exhaustion (Bailey, Davis, & Ahlborn, 1993) , leading to the suggestion that depletion of central catecholamines may be related to fatigue during strenuous exercise. Increasing catecholaminergic neurotransmission through the administration of centrally acting drugs has been demonstrated to produce improvements to exercise performance in the heat, with no effect apparent when exercise was undertaken in temperate conditions . However, clear improvements in performance have been reported in temperate conditions when more potent dopaminergic drugs are administered before exercise (amphetamine : Gerald, 1978 ; apomorphine: Heyes, Garnett, & Coates, 1988) .
The precursor for catecholamine synthesis in the CNS is the nonessential amino acid tyrosine (TYR), and synthesis is tightly controlled through the activity of the rate-limiting enzyme tyrosine hydroxylase (TH), with subtle differences in the mechanism of regulation apparent between NA and DA neurons (Cooper, Bloom, & Roth, 2003) . Under normal conditions, cerebral TYR availability is typically in excess of K m for TH, meaning that that the provision of additional TYR should not alter the synthesis of DA/NA. The large neutral amino acids (LNAAs), including TYR, compete for transport across the blood-brain barrier via the L-type amino-acid carrier, and carrier saturation and competitive inhibition of the influx of other LNAAs can be expected at supraphysiological plasma concentrations of a particular amino acid. Consequently, an elevation in circulating TYR concentrations will result in a greater uptake of TYR at the expense of the other LNAAs, in turn producing greater braintissue concentrations of TYR (Bongiovanni, Kirkbride, Newbould, Durkalski, & Jaskiw, 2010) . TYR administration has been demonstrated to increase noradrenergic neurotransmission in rats exposed to periods of stress (Lehnert, Reinstein, Strowbridge, & Wurtman, 1984; Reinstein, Lehnert, Scott, & Wurtman, 1984) , with little effect apparent while under resting conditions . Evidence for an effect on brain DA/NA under resting conditions is mixed, but a microdialysis study did report a modest transient rise in extracellular DA in the striatum (During, Acworth, & Wurtman, 1989) .
To date, few studies have demonstrated a positive effect of TYR supplementation on physical performance. Struder et al. (1998) failed to observe any change in the capacity to perform prolonged exercise after the ingestion of a 20-g dose of TYR immediately before and during exercise. Similarly, no effect on time-trial performance was apparent after ingestion of a 25-mg/kg dose of TYR (Chinevere, Sawyer, Creer, Conlee, & Parcell, 2002) . TYR supplementation is also reported to produce no measurable effect on endurance, muscle strength, or anaerobic power (Sutton, Coill, & Deuster, 2005) . However, a recent study reported a marked improvement (15% ± 11%) in exercise capacity when prolonged exercise was undertaken in warm conditions (Tumilty, Davison, Beckmann, & Thatcher, 2011) . Since several lines of evidence suggest that changes in catecholaminergic neurotransmission are an important mediator of fatigue during exercise in the heat Watson et al., 2005) , these findings warrant further investigation.
While evidence for an effect of TYR on physical performance is limited, stress-related decrements in mood and task performance appear to be attenuated by TYR supplementation. Both DA and NA have been implicated in a variety of stress-related behaviors, and the catecholamines play a key role in modulating the central stress response. Catecholamine synthesis is significantly upregulated during arousal and stress, and acute exposure to stress has been demonstrated to result in the partial depletion of catecholamines in some brain regions, including the hippocampus, striatum, and midbrain (Bailey et al., 1993; Lehnert et al., 1984; Palkovits, Kobayashi, Kizer, Jacobowitz, & Kopin. 1975) . This reduction in extracellular catecholamine concentrations may be important in the loss of motor control observed under these conditions. Several reports indicate that TYR ingestion improves stress-induced cognitive and behavioral deficits, in particular maintenance of working memory, object tracking, and stress-sensitive attentional focus tasks (Banderet & Lieberman, 1989; Deijen, Wientjes, Vullinghs, Cloin, & Langefeld, 1999; Lieberman, Georgelisa, Maherb, & Yeghiayan, 2005; Mahoney, Castellani, Kramer, Young, & Lieberman, 2007; Neri et al., 1995; Shurtleff, Thomas, Schrot, Kowalski, & Harford. 1994) . The provision of exogenous TYR appears to enable the maintenance of catecholamine production during periods of stress, when presumably the activity of TH is up-regulated .
The available evidence suggests that TYR supplementation may improve the ability to cope with acute stress when one is exposed to challenging environments. The aim of the current study was to further examine the influence of acute TYR supplementation on prolonged exercise capacity and cognitive function during exercise in a warm environment.
Methods

Subjects
Eight trained male volunteers were recruited to participate in this study (M ± SD; age 23 ± 3 years, height 1.82 ± 0.06 m, body mass 80.0 ± 9.6 kg, VO 2max 5.2 ± 0.3 L/ min). Before volunteering, participants received written information regarding the nature and purpose of the study. After an opportunity to ask any questions, a written statement of consent was signed. All participants were physically active and took part in competitive team or endurance sports but were not acclimated to exercising in a warm environment. The experimental protocol was approved by the local ethical advisory committee (ref:
Experimental Protocol
All subjects completed an initial maximal exercise test, two familiarization trials, and two experimental trials (placebo [PLA] and TYR). The preliminary trial consisted of incremental cycle exercise to volitional exhaustion on an electronically braked cycle ergometer (Lode Corival, Groningen, Holland) and was used to determine VO 2max and the power output required to elicit 70% VO 2max . The two familiarization trials were undertaken to ensure that the subjects were accustomed to the procedures employed during the investigation and to minimize any learning effect. These were also intended to ensure that the volunteers were familiar with the sensation of exhaustive exercise and capable of consistently producing a maximal effort. All trials were separated by at least 7 days to minimize the development of heat acclimation, and experimental trials were completed in a counterbalanced, randomized order. Subjects were instructed to record dietary intake and physical activity during the 24 hr before the first trial and to replicate this on the day before each subsequent experimental trial. No strenuous exercise or alcohol consumption was permitted in the 24 hr before each trial.
Participants arrived in the laboratory in the morning after an overnight fast, with the exception of ingesting 500 ml of plain water 90 min before arrival. On arrival, each participant emptied his bladder into a plastic container; the volume of urine produced was recorded and an aliquot retained for measurement of osmolality (Gonotec Osmomat 030, YSI, Farnborough, UK). Nude body mass was then measured to the nearest 10 g (Adam AFW-120K, Milton Keynes, UK). Subjects inserted a rectal thermistor (Grant Squirrel SQ800, Cambridgeshire, UK) 10 cm beyond the anal sphincter for measurement of core temperature. A heart-rate telemetry band (Polar Beat, Kempele, Finland) was positioned, and surface skin-temperature probes (Grant Squirrel SQ800, Cambridgeshire, UK) were attached to four sites (chest, upper arm, thigh, and calf) to enable the calculation of weighted mean skin temperature (Ramanathan, 1964) .
Subjects then rested in a seated position for 15 min in a comfortable environment (22-23 °C) with one hand immersed in warm water (42 °C) for 10 min. A 21-g cannula was introduced into a superficial vein of the prewarmed forearm to enable repeated blood sampling, with the cannula flushed with a small volume of heparinized saline after each collection. An initial resting 5-ml blood sample was collected. Participants then completed a computer-based cognitive-function test battery (lasting around 15 min) that included the Stroop word and color test (Stroop, 1935 ), Sternberg's memory-scanning task (Sternberg, 1966) , and a rapid visual informationprocessing task (Coull, Frith, Frackowiak, & Grasby, 1996) .
After completing the cognitive-function tests, subjects consumed 250 ml of either a PLA (sugar-free fruit drink, Tesco Ltd., Cheshunt, UK) or a TYR solution (sugar-free fruit drink with TYR; SHS Intl., Liverpool, UK) and remained at rest for a further 60 min. Another 250 ml of the appropriate solution was ingested after 30 min of rest. The quantity of TYR ingested during this trial equaled 150 mg/kg body mass (12.01 ± 1.44 g). This dose of TYR has been previously reported to enhance exercise capacity in the heat (Tumilty et al., 2011) , and similar quantities have been shown to be effective in attenuating reductions in cognitive function after periods of stress (Banderet & Lieberman, 1989; Deijen et al., 1999; Mahoney et al., 2007; Neri et al., 1995; Shurtleff et al., 1994) . The drinks were indistinguishable in taste and were served in opaque bottles to disguise the nature of the solution ingested. After 45 min of rest, a second cognitive-function test battery was completed. At the end of the rest period a second blood sample was drawn.
Participants then entered a climatic chamber maintained at 30.2 ± 0.2 °C, an air velocity of 1-1.5 m/s, and a relative humidity of 50% ± 1% and began cycle exercise at a workload equivalent to an intensity of 69% ± 3% VO 2max (208 ± 23 W). At 10-min intervals, they ingested 150 ml of the appropriate drink. Subjects were not permitted to consume any other fluids throughout the trial. No feedback was given with regard to time elapsed or any measurements taken. Exercise continued until volitional exhaustion, defined as an inability to maintain a pedal cadence of >60 rpm despite verbal encouragement from the investigators. At the point of exhaustion, subjects returned to the temperate environment to complete a final set of cognitive-function tests. The probes and cannula were then removed, and participants were reweighed nude to enable the calculation of body mass and sweat losses.
Measures
Weighted mean core temperature , weighted mean skin temperature, and heart rate were recorded at 15-min intervals throughout the rest period, every 5 min during exercise, and at the point of exhaustion. Ratings of perceived exertion (Borg, 1982) and of thermal stress (using a 21-point scale ranging from -10, unbearable cold, to +10, unbearable heat) were assessed at 10-min intervals and at the point of exhaustion. Expired air was collected at 15-min intervals during exercise using the Douglas bag method. These data were used to calculate fuel-oxidation rates (Péronnet & Massicotte, 1991) . Blood samples were taken at 15-min intervals and at the point of exhaustion.
Blood samples (5 ml) were drawn directly into dry syringes. A 1-ml aliquot was dispensed into tubes containing K 2 EDTA; this was used to determine hemoglobin concentration (using the cyanmethemoglobin method) and hematocrit (via microcentrifugation). These data were used to estimate percentage changes in blood, red cell, and plasma volumes relative to the resting sample (Dill & Costill, 1974) . Duplicate 100-μl aliquots of whole blood were rapidly deproteinized in 1 ml of 0.3-N perchloric acid. These were centrifuged, and the resulting supernatant was used to determine glucose concentrations using a commercially available assay (GOD-PAP, Randox Ltd., Crumlin, UK). The remaining 4 ml was placed in a plain tube and left to clot at room temperature for 1 hr before being centrifuged to yield serum, which was then stored at -80 °C. Serum (500 μl) for amino acid analysis was deproteinized using 12.5 μl 12-M PCA containing 40 mM norvaline as an internal standard. The resulting supernatant was stored on ice and neutralized with an equal volume of freon-trioctylamine (78% v/v 1,1,2-trichlorotrifluoroethane, 22% v/v trioctylamine). Amino acid concentrations of the filtered extract were determined by reverse-phase HPLC with ultraviolet detection using a Zorbax eclipse AAA column (4.6 × 75 mm, 3.5 μm) with precolumn derivatization using orthophthalaldehyde (Henderson, Ricker, Bidlingmeyer, & Woodward, 2000) . Serum free-fatty-acid concentrations were measured using a commercially available assay kit (Roche Diagnostics, Mannheim, Germany).
Statistical Analysis
Data are presented as M ± SD unless otherwise stated. Differences in exercise time to exhaustion, pretrial urine osmolality, and sweat rate were examined using paired t tests. Cohen's d effect size (ES) for the differences in exercise time was also determined. To identify differences in data collected throughout each trial, two-way (timeby-trial) ANOVAs were employed. Where a significant interaction was apparent, pairwise differences were evaluated using the Bonferroni post hoc procedure.
Results
Preexercise body mass was not different between trials (p = .577). There were also no differences in preexercise urine osmolality (p = .207), blood glucose (p = .734), or core temperature (p = .198), suggesting that subjects began each trial in a similar physiological state. There was no order effect on time to fatigue across the two experimental trials (p = .826). Supplementation with TYR had no effect on exercise time to exhaustion, with times of 61.4 ± 13.7 min and 60.2 ± 15.4 min recorded in the PLA and TYR trials, respectively (p = .505, ES = 0.09; Figure 1) . Figure 2 illustrates changes in core (upper panel) and skin (lower panel) temperature during each experimental trial. Weighted mean core temperature at the start of the trials was 37.2 ± 0.2 °C, and there was a gradual reduction apparent during the 1-hr rest period in both trial conditions (p = .049). Weighted mean core temperature increased during exercise (p < .001), reaching 39.2 ± 0.3 °C at the point of exhaustion in the PLA trial and 39.3 ± 0.3 °C when TYR was ingested. This response was not different between trials (p = .554). The weighted mean skin temperature increased from 30.9 ± 0.3 °C and 31.3 ± 0.6 °C at rest to 33.8 ± 1.0 °C and 33.4 ± 0.9 °C at the end of exercise in PLA and TYR trials, respectively (p < .001). The solution ingested did not influence this response (p = .167). Mean sweat rate was 30 ± 6 ml/ min in the PLA trial and 29 ± 5 ml/min when TYR was ingested (p = .850).
Heart rate increased throughout both trials (p < .001); at exhaustion values of 175 ± 11 beats/min and 177 ± 7 beats/min were recorded in the PLA and TYR trials, respectively (p = .380). TYR ingestion did not influence ratings of perceived exertion (p = .179) or thermal stress recorded during exercise (p = .691). Oxygen uptake (p = .296) and respiratory-exchange ratio (p = .449) were not different between treatments, and there was no difference in the calculated rates of fat (p = .256) and carbohydrate (p = .627) oxidation apparent between trial conditions.
Resting blood glucose concentrations were 4.1 ± 0.2 mmol/L in PLA 4.2 ± 0.3 mmol/L in TYR (Table 1) . Blood glucose concentration increased over the course of each trial (p < .001), but the treatment did not influence this response (p = .612). Serum free-fatty-acid concentrations also increased during the exercise bout (p < .001), with no differences between trials (p = .557). At the end of the rest period, the percentage changes in blood and plasma volumes were significantly greater in the TYR trial than after PLA ingestion (both p < .05; Table 1 ). This difference was not maintained during exercise, with no further effect of trial on blood (p < .05) or plasma (p < .05) volumes.
Serum amino acid concentrations are presented in Table 2 . Baseline serum TYR concentrations were not different between trials (PLA 52 ± 8 μmol/L, 55 ± 6 μmol/L; p = .511). Ingestion of the TYR solution produced a marked elevation in circulating TYR concentration (+236 ± 46 μmol/L) by the end of the 1-hr rest period (p < .001), with this increase maintained throughout exercise. No change in serum TYR was apparent during the PLA trial (p = .924). TYR ingestion did not influence circulating concentrations of valine (p = .413), leucine (p = .391), isoleucine (p = .726), tryptophan (p = .076), phenylalanine (p = .552), or methionine (p = .617). Consequently, TYR ingestion produced a significant increase in the serum concentration ratio of TYR to the other LNAAs that was maintained throughout exercise (p < .001; Figure  3 ). No change in TYR:LNAA was apparent in the PLA trial (p = 0774). In addition, there was a modest reduction in the serum concentration ratio of tryptophan to the other LNAAs when TYR was ingested (p < .001).
Perceived exertion increased with time during both trials (p < .001), reaching values of 20 ± 0 and 20 ± 1 at exhaustion in the PLA and TYR trials, respectively. This response was not influenced by the drink ingested (p = .179). Perceived thermal stress increased progressively throughout both trials (p < .001), with no differences observed between trials (p = .247). Exercise caused an increase in error rate during the complex component of the Stroop test (p = .034), but there were Note. RVIP = rapid visual information processing. *Significant difference from the prerest value (p < .05).
Figure 3 -The serum concentration ratio between tyrosine (TYR) and the remaining large neutral amino acids (LNAA) during the placebo and tyrosine trials (M ± SD). **Significant difference (p < .001) from the corresponding time point in the placebo trial.
Discussion
Reductions in exercise capacity brought about by warm conditions are thought to be mediated, at least in part, through events occurring in the CNS (Nybo, 2010) . A high brain temperature, coupled with feedback from skin thermoreceptors and increased cardiovascular stress, appears to result in impaired voluntary muscle activation, a reduced drive to continue exercise, and ultimately reduced performance. Previous studies have demonstrated that pharmacological Watson et al., 2005) and nutritional (Tumilty et al., 2011) manipulation of central catecholaminergic neurotransmission can produce significant improvements in performance during exercise undertaken when the ambient temperature is high. Since DA and NA are intrinsically involved in motivation, arousal, reward, attention, and motor control, it appears likely that strategies that increase catecholaminergic neurotransmission during exercise dampen or override inhibitory signals arising from the CNS to cease exercise due to hyperthermia enabling the maintenance of a high power output and improved performance. Generally, these effects are not present in studies where exercise is undertaken in temperate conditions (Chinevere et al., 2002; Meeusen, Roeykens, Magnus, Keizer, & De Meirleir, 1997; Struder et al., 1998; Watson et al., 2005) , unless the manipulation is particularly potent (for example, amphetamine or apomorphine administration; Gerald, 1978; Heyes et al., 1988) . Selective noradrenaline agonists (e.g., reboxetine), which produce little or no effect on the dopaminergic system, do not positively influence exercise performance (Roelands, Goekint, et al., 2008) . This is possibly because the peripheral actions of these drugs result in a higher resting and exercise heart rate. The results of this study demonstrate no effect of TYR supplementation on exercise capacity in a warm environment. While studies have reported similar effects in temperate conditions (Chinevere et al., 2002; Struder et al., 1998) , the current findings are contrary to a recent report that demonstrated a 15% ± 11% improvement in exercise capacity after the ingestion of TYR before exercise in the heat. To date, that is the only study to demonstrate a beneficial effect of TYR supplements on exercise performance. While the current experimental design was similar to that employed by Tumilty et al. (2011) , with a comparable exercise protocol, dosage, and timing of supplement ingestion, the outcome appears very different. Ingestion of apparently the same dose of TYR produced a ~4.6 ± 1.0-fold increase in circulating TYR concentrations before exercise in the current study, with a smaller response reported by Tumilty et al. (~threefold) . In both cases, there was a marked increase in the serum concentration ratio of TYR to the remaining LNAAs, creating an environment that would be expected to promote increased TYR transport across the blood-brain barrier. Perhaps it is worth noting that the amino acid provided in the current study was sourced from a medical nutrition supplier, and TYR content was verified through analysis of a solution prepared to contain 100 μmol/L using the HPLC method described previously. The TYR administered in the study of Tumilty et al. was obtained from an online sport-nutrition company. This may be an important consideration, given the widely acknowledged uncertainty regarding the composition of some sportnutrition supplements (Maughan, 2005) .
There are very few data regarding an effective or safe dose for TYR supplementation. As stated previously, the dose employed in this study has been previously reported to improve exercise capacity in the heat (150 mg/kg; Tumilty et al., 2011) , and quantities of 100-300 mg/kg have been shown to be effective in attenuating reductions in cognitive function caused by periods of stress (Banderet & Lieberman, 1989; Deijen et al., 1999; Mahoney et al., 2007; Neri et al., 1995; Shurtleff et al., 1994) . Higher TYR doses have been administered (25 mg/kg), with no effect on time-trial performance reported (Chinevere et al., 2002) . Since several studies undertaken in temperate conditions reported no change in performance after nutritional (Struder et al., 1998; Sutton et al., 2005) and pharmacological manipulation of DA and NA Watson et al., 2005) , perhaps the findings of Chinevere et al. (2002) are not wholly surprising.
Catecholamine synthesis in the CNS is tightly regulated through changes in the activity of TH. Neuronal firing rate, the impulse flow through the nigrostriatal pathway, and the amount of DA/NA synthesized (endproduct inhibition) and released (feedback inhibition) all govern TH activity to varying degrees depending on the neuron type and location (Cooper et al., 2003) . While there is limited evidence that the provision of additional TYR may result in a transient increase in the rate of DA synthesis (During et al., 1989) , under basal conditions cerebral levels of TYR (~1 nmol/mg in rodents; Bongiovanni et al., 2010) are in excess of the K m for TH. Consequently, the uptake of additional TYR across the blood-brain barrier, resulting from an increase in the plasma concentration ratio of TYR to the other LNAAs, should not result in any significant change in the rate of DA/NA synthesis . Receptor-mediated feedback mechanisms are also likely to limit the magnitude and duration of any effect, with larger doses of TYR likely to activate this response to a greater degree (During et al., 1989 ). This situation is very different from that observed in serotonergic neurons, where little or no end-product inhibition exists, tryptophan hydroxylase is not saturated, and tryptophan hydroxylase does not need to be in an active form; thus, the provision of more substrate (tryptophan) increases central serotonin production. Increased catecholamine synthesis can be achieved through administration of drugs that up-regulate TH activity (DA/NA agonists, caffeine, and morphine), the administration of L-dopa (which bypasses this rate-limiting step), or exposure to periods of significant physiological and/or emotional stress .
The factors involved in the regulation of TH activity perhaps explain the discrepancy between the exercise literature and the positive findings of studies employing TYR administration to offset decrements in aspects of cognitive function in military settings. Catecholamine turnover is significantly up-regulated in response to arousal and stress, and acute exposure to stress has been demonstrated to result in the depletion of catecholamines in some brain regions . There is a significant body of literature demonstrating that TYR supplementation in doses of 100-300 mg/kg can reduce cognitive and behavioral deficits occurring in response to a variety of stressful situations including exposure to cold (Mahoney et al., 2007; Shurtleff et al., 1994) and hypoxia (Banderet & Lieberman, 1989) , during periods of sleep deprivation (Neri et al., 1995) , and when undertaking sustained periods of combat training (Deijen et al., 1999) . While strenuous exercise has been reported to improve aspects of cognitive function (Hogervorst, Riedel, Jeukendrup, & Jolles, 1996) , mental performance may be impaired when core temperature increases (Lieberman et al., 2005; Simmons, Saxby, McGlone, & Jones, 2008) . Since TYR has been demonstrated to attenuate these hyperthermia-induced decrements in rodents (Lieberman et al., 2005) , it seems plausible that the preservation of cognitive performance could be an additional benefit of TYR supplementation during exercise in the heat. The current study showed no change in response time or error rate during simple tasks requiring short-term or working memory, but an increase in the number of errors was apparent at the end of exercise when the task required more complex information processing (Stroop incongruent condition) . No further effects were apparent, with no differences observed between the trials, suggesting that exhaustive exercise in warm conditions was not sufficient to produce a significant decrement in the measured components of cognitive function. Since improvements in aspects of cognitive function have been reported after intense exercise in temperate conditions (Hogervorst et al., 1996) , it is possible that the addition of heat stress will limit any benefit resulting from exercise.
Since catecholaminergic and serotonergic projections innervate areas of the hypothalamus, changes in the activity of these neurons have been implicated in the control of body temperature during exercise . A change in catecholamine synthesis may therefore be expected to result in differences in the thermoregulatory response to exercise. In the current study, ingestion of TYR failed to produce any clear effect on core or skin temperature or on perceived thermal comfort. Exercise resulted in a progressive increase in core temperature during both trials, with values of 39.0 ± 0.4 °C and 39.0 ± 0.5 °C recorded at exhaustion. While the significance of elevated core temperature for performance during prolonged dynamic exercise has been questioned in recent years, an interplay between core, brain, and skin temperature does appear to be important in fatigue, as highlighted by recent studies (Cheuvront et al., 2010; Maughan et al., 2012) . For the most part, the decision to adjust pace or to terminate exercise altogether is a conscious one, dictated by the subjective perception of the balance between the drive to continue exercise and the desire to seek respite by stopping (Cabanac, 2006) . Consequently, it is clear that the CNS plays an integral role in the fatigue process, since motivation, arousal, and reward have a sound neurobiological basis that can be manipulated by pharmacological means (Gerald, 1978; Watson et al., 2005) .
In conclusion, acute oral supplementation of 150 mg/ kg BM TYR did not influence exercise capacity in the heat, measures of cognitive function, or the physiological response to exercise compared with a PLA condition.
Although it is possible to significantly increase the uptake of TYR across the blood-brain barrier, there is limited evidence that the provision of TYR can increase brain DA/NA synthesis under normal conditions. It appears likely that these neurons are responsive to increased precursor supply only during periods of chronic stress over and above those encountered in most exercise situations.
